Shin Sung, Jung Chang Hee, Choi Ji Yoon, Kwon Hyun Wook, Jung Joo Hee, Kim Young Hoon, Han Duck Jong
Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Asan Diabetes Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
PLoS One. 2018 Jan 29;13(1):e0191421. doi: 10.1371/journal.pone.0191421. eCollection 2018.
Limited data are available regarding optimal selection criteria for pancreas transplant alone (PTA) to minimize aggravation of diabetic nephropathy.
A total of 87 type 1 diabetic patients were evaluated before and after PTA at a single center from January, 1999 to December, 2015, together with 87 matched non-transplanted type 1 diabetic subjects who were candidates for PTA to compare deterioration of native kidney function. A total of 163 patients (79 in the transplanted group and 84 in the nontransplanted group) were finally enrolled after excluding nine patients with estimated glomerular filtration rate less than 60 mL/min/1.73 m2 and two patients with moderate proteinuria (≥ 1.5 g/day).
A total of seven recipients (8.9%) had end-stage renal disease post-transplant whereas only one patient (1.2%) developed end-stage renal disease in the nontransplanted group during their follow-up period (median 12.0, range 6-96 months) (p = 0.03). Furthermore, a composite of severe renal dysfunction and end-stage renal disease (31.6% vs 2.4%) was significantly higher in the transplanted group (p < 0.001). Multivariate Cox regression analysis revealed that a higher level of tacrolimus at six months post-transplant (HR = 1.648, CI = 1.140-2.385, p = 0.008) was the only significant factor associated with end-stage renal disease.
There is a considerable risk for deterioration of renal function in PTA recipients post-transplant compared with non-transplant diabetic patients. With rather strict selection criteria such as preoperative proteinuria and estimated glomerular filtration rate, PTA should be considered in diabetic patients to minimize post-transplant aggravation of diabetic nephropathy.
关于单纯胰腺移植(PTA)的最佳选择标准,以尽量减少糖尿病肾病恶化的数据有限。
1999年1月至2015年12月期间,在单一中心对87例1型糖尿病患者进行了PTA前后的评估,并与87例匹配的非移植1型糖尿病受试者(他们是PTA的候选者)进行比较,以观察其自身肾功能的恶化情况。在排除9例估计肾小球滤过率低于60 mL/min/1.73 m2的患者和2例中度蛋白尿(≥1.5 g/天)的患者后,最终纳入了163例患者(移植组79例,非移植组84例)。
共有7例受者(8.9%)移植后出现终末期肾病,而非移植组在随访期间(中位时间12.0个月,范围6 - 96个月)只有1例患者(1.2%)发展为终末期肾病(p = 0.03)。此外,移植组严重肾功能不全和终末期肾病的综合发生率(31.6%对2.4%)显著更高(p < 0.001)。多因素Cox回归分析显示,移植后6个月较高水平的他克莫司(HR = 1.648,CI = 1.140 - 2.385,p = 0.008)是与终末期肾病相关的唯一显著因素。
与未移植的糖尿病患者相比,PTA受者移植后肾功能恶化的风险相当大。通过相当严格的选择标准,如术前蛋白尿和估计肾小球滤过率,应考虑对糖尿病患者进行PTA,以尽量减少移植后糖尿病肾病的加重。